Navigation Links
Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
Date:10/8/2008

CALGARY, Oct. 8 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has successfully completed initial scale up of its manufacturing process for REOLYSIN(R) to commercial scale.

The scale up of primary production and downstream processing development was undertaken by the National Research Council Biotechnology Research Institute (NRC-BRI) located in Montreal, Canada.

"Our existing manufacturing capacity at 40 litres allows us to support future pivotal clinical studies with REOLYSIN(R)," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "Using this process, a 100-litre manufacturing facility has the potential to produce more than one million doses a year for intravenous use."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the manufacturing process, the transfer of the scale up to full cGMP production, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and developme
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... Cambridge Healthtech Institute will host its fifth annual ... Renaissance Waterfront Hotel in Boston, MA. The ten ... the current strategies and innovations for optimizing bioprocesses while ... the field will reveal how their work has resulted ... and efficiency. , “In this age of rapid innovation, ...
(Date:5/16/2013)... 2013  HealthSparq, a trusted provider of healthcare ... regional health plans, will debut a new benchmark ... Institute 2013 conference on June 13.  The presentation ... health insurance companies across the country are thinking ... demands for increased healthcare transparency. ...
(Date:5/16/2013)... 16, 2013 Scientists at the Center for ... , and the California -based biopharmaceutical ... novel therapy for reversing memory decline in mice with ... significant cognitive improvement in advanced stage AD mice. The ... reversing cognitive decline for advanced stage AD mice, and ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 On average, ... costs over one billion dollars. Despite this investment, less ... stakes this high, is your clinical trial design optimally ... the best outcomes? , Dr. Frederic Sax, Global Head ... discuss the use of data, information and technology in ...
Breaking Biology Technology:The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2
... ASHBURN, Va., March 31 - Innocoll, Inc. announced that ... 510k application for its CollaRx(TM) Lidocaine Sponge for the ... each year 13 million patients worldwide suffer from chronic ... etc.) 35 percent of all chronic wounds do ...
... Make Soyfoods Even HealthierST. LOUIS, March 31 Recent ... soy to be beneficial to the diet. And, the ... food products such as soyfoods even healthier. These findings ... Attitude Survey - sponsored by the United Soybean ...
... manufacturing, Selexis is now offering a portfolio of ... added characterization servicesGENEVA, March 31 Selexis SA, ... for the rapid development of high-performance stable production ... on the biosimilar market segment. Under the ...
Cached Biology Technology:Innocoll, Inc. Files 510 (k) Application for CollaRx Lidocaine Sponge 2Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 2Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 3Selexis Launches Biosimilar Cell Line Development Program 2
(Date:5/16/2013)... are about 23 million years old give unprecedented ... order, one of the most species-rich groups among ... paleontologist Professor Bettina Reichenbacher from the Division of ... and Environmental Sciences at Ludwig-Maximilians-Universitaet (LMU) in Munich ... fish fossils which they assign to the group ...
(Date:5/16/2013)... around the world are meeting next week in ... showcase the latest in research findings about the ... understanding the disorders that affect them., "Canada is ... will showcase the best of neuroscience research done ... President of the Canadian Association for Neuroscience. He ...
(Date:5/16/2013)... YORK , May 16, 2013 /PRNewswire/ ... research report is available in its catalogue: ... Forecast & Opportunities, 2018 ... protection and old security practises such as ... the growth of biometric technologies in last ...
Breaking Biology News(10 mins):Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 37th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7
... is not as well known as other, more widely used ... fly, nematode or mouse. But University of Illinois cell and ... it turns out, the tiny, seemingly cross-eyed flatworm is an ... eggs and sperm in all sexually reproducing species. , ...
... has puzzled scientists for decades, MIT and Harvard researchers ... of vitamin B12-the only vitamin synthesized exclusively by microorganisms. ... is essential for human health. Four Nobel Prizes have ... fragment of the molecule remained an enigma-until now. ...
... Cincinnati (UC) environmental health researchers say a therapy commonly ... the body may also improve muscle functions associated with ... Led by Amit Bhattacharya, PhD, the UC team found ... a 19 percent improvement in their ability to perform ...
Cached Biology News:Study of planarians offers insight into germ cell development 2MIT biologists solve vitamin puzzle 2MIT biologists solve vitamin puzzle 3Lead-'scrubbing' drug may also improve muscle function in lead-exposed children 2